Founded in London by Dr. Alexander Hartley, a Cambridge University medical doctor (and a male endocrinologist), and biotechnology entrepreneur James Faulkner, the company’s initial goal was to break away from the traditional fragmented approach to men’s health and establish a precision health system centered on biomarker-guided navigation.

The first laboratory: A research and development laboratory was established at the King’s College London Innovation Incubator, focusing on hormone dynamic mapping and early identification technology for metabolic risks.

Patent Technology Release: Successfully developed the Vitality Coordinate System™, integrating 132 biomarkers and AI dynamic assessment algorithms to achieve millimeter-level localization of male health imbalances.

Clinical Validation: A first-round clinical study (n=320) completed in collaboration with University College London Hospitals (UCLH) demonstrated that the system achieves a 94.7% accuracy rate in identifying low testosterone, metabolic syndrome, and chronic fatigue.

VIP Program Launched: The Platinum Circle annual membership program, limited to 100 members, quickly gained favor among executives and entrepreneurs in the City of London.

The Vitality Point research team comprises leading experts in six fields: endocrinology, urology, functional medicine, genomics, exercise physiology, and data science. Core members are all graduates of top medical schools in the UK and Europe and possess many years of clinical research experience. Adhering to the core concept of “precisely locating health imbalances,” the team continuously advances the technological iteration and clinical translation of the “Vitality Coordinate System.”

Currently, the research team has grown to over 150 members.

University of Cambridge School of Clinical Medicine: Jointly conduct the “Men’s Midlife Health Turning Point” cohort study (n=2,500)

University College London Hospitals (UCLH): Early prostate health screening project (2023-2025)

Imperial College London Institute for Data Science: Jointly develop an AI-powered dynamic health early warning system

Royal Society of Medicine (RSM): Participate in the development of the “UK Private Men’s Health Service Standards 2024”

“Application of Multi-omics Analysis in Male Vitality Assessment.” *Journal of Men’s Health*, 2024; 20(3): 112-125. (Impact Factor: 6.7)

“A Novel Algorithm for Male Metabolic Risk Stratification.” *The Lancet Digital Health*, 2023; 5(8): e489-e501. (Impact Factor: 24.8)

“Precision Guidance for Functional Outcomes after Prostate Interventional Therapy.” *European Focus on Urology*, 2025; 11(1): 34-42. (Impact Factor: 5.6)

VTL has been included in the Royal Society of Medicine (RSM)’s “Recommended Innovative Technologies for Men’s Health” list.

We have partnered with two teaching hospitals under NHS England to conduct early prostate health screening programs, covering more than 5,000 high-risk men.